Global Oncolytic Virus Market Research Report 2023(Status and Outlook)
Report Overview
An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumor. Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.
To date, two genetically engineered oncolytic viruses have been approved for marketing as drugs. One is Oncorine (H101, the same construct as ONYX‐015),9 an E1B‐deleted adenovirus, which was approved in China for head and neck cancer and esophagus cancer in 2005. The use and clinical data of Oncorine is so far limited to China. The other is T‐Vec (talimogene laherparepvec, IMLYGIC, formerly OncoVEXGM‐CSF), which was approved for melanoma by the FDA in the USA in October 2015 and was subsequently approved in Europe in January 2016 and in Australia in May 2016. For developing product, there are 3 products in Phase 3, 8 products in Phase 2, 7 products in Phase 1 and 3 products in Preclinical. Market competition is intense. Amgen, Shanghai Sunway Biotech, Oncolytics Biotech, Viralytics, Transgene SA are the leading developers in the industry; with high investment in research marketing and they will monopoly position in the industry. Other players include Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma, Genelux Corporation, Vyriad, TILT Biotherapeutics and Cold Genesys, etc.
The Global Oncolytic Virus Market Size was estimated at USD 16 million in 2022 and is projected to reach USD 25.36 million by 2029, exhibiting a CAGR of 6.80% during the forecast period.
Bosson Research’s latest report provides a deep insight into the global Oncolytic Virus market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oncolytic Virus Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oncolytic Virus market in any manner.
Global Oncolytic Virus Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Amgen
Shanghai Sunway Biotech
Market Segmentation (by Type)
Imlygic
Oncorine
Others
Market Segmentation (by Application)
Park
Residential
Factory
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Oncolytic Virus Market
Overview of the regional outlook of the Oncolytic Virus Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors